Alvotech to release third quarter 2026 financial results in November
Biotechnology firm Alvotech will disclose its financial performance for the nine months ended September 30, 2026, on November 11, 2026, following the close of U.S. markets.
Reykjavik-based Alvotech announced it will report its financial results for the third quarter and the first nine months of 2026 on November 11, 2026. The announcement is scheduled for after the close of the U.S. stock exchanges.
Following the release, the company will host a live webcast featuring a question-and-answer session on November 12, 2026, at 08:00 ET. The event provides an opportunity for investors to review the company’s recent performance and strategic progress.
Alvotech develops and manufactures biosimilar medicines. The company currently has several products approved in international markets, targeting conditions such as autoimmune disorders and cancer. Its current pipeline aims to expand its portfolio across various therapeutic areas.
Financial materials and presentation slides will be available on the company’s investor relations website prior to the scheduled webcast.